Consistent with its metabolic benefits, the reduced level of adiponectin in the circulation is correlated with a number of human malignancies, including diabetes, inflammation, obesity, fibrosis, and cardiovascular disease. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.